Did The US Jump The Gun With The New Omicron-Targeted Vaccines?

This article is for premium subscribers. Please sign up here for a tax-deductible subscription. 

If you're a premium subscriber, sign in below. 

Op-ed calls for more information about cost versus benefit as vaccine-makers prepare to hike prices.

Subscribe to marketing